Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J; CETLAM Group. Nomdedéu JF, et al. Among authors: bargay j. Leukemia. 2013 Nov;27(11):2157-64. doi: 10.1038/leu.2013.111. Epub 2013 Apr 15. Leukemia. 2013. PMID: 23584566
Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies).
Bussaglia E, Pratcorona M, Carricondo M, Sansegundo L, Rubio MA, Monter A, Brell A, Badell I, Esteve J, Arnan M, Talarn C, Tormo M, García A, Vall-Llovera F, Ortin X, Pedro C, Bargay J, Brunet S, Sierra J, Nomdedéu J. Bussaglia E, et al. Among authors: bargay j. Ann Hematol. 2020 Apr;99(4):765-772. doi: 10.1007/s00277-020-03910-0. Epub 2020 Feb 15. Ann Hematol. 2020. PMID: 32062741 Clinical Trial.
Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
Perea G, Domingo A, Villamor N, Palacios C, Juncà J, Torres P, Llorente A, Fernández C, Tormo M, Queipo de Llano MP, Bargay J, Gallart M, Florensa L, Vivancos P, Martí JM, Font L, Berlanga J, Esteve J, Bueno J, Ribera JM, Brunet S, Sierra J, Nomdedéu JF; CETLAM GroupSpain. Perea G, et al. Among authors: bargay j. Leuk Res. 2005 Oct;29(10):1109-16. doi: 10.1016/j.leukres.2005.02.015. Leuk Res. 2005. PMID: 16095690
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G, Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Martí JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedéu JF; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Perea G, et al. Among authors: bargay j. Leukemia. 2006 Jan;20(1):87-94. doi: 10.1038/sj.leu.2404015. Leukemia. 2006. PMID: 16281071
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size.
Nomdedeu J, Bussaglia E, Villamor N, Martinez C, Esteve J, Tormo M, Estivill C, Queipo MP, Guardia R, Carricondo M, Hoyos M, Llorente A, Juncà J, Gallart M, Domingo A, Bargay J, Mascaró M, Moraleda JM, Florensa L, Ribera JM, Gallardo D, Brunet S, Aventin A, Sierra J; Spanish CETLAM. Nomdedeu J, et al. Among authors: bargay j. Leuk Res. 2011 Feb;35(2):163-8. doi: 10.1016/j.leukres.2010.05.015. Epub 2010 Jun 9. Leuk Res. 2011. PMID: 20542566 Clinical Trial.
MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, Gallardo D, Heras I, Queipo de Llano MP, Bargay J, Monzo M, Sierra J, Navarro A, Esteve J; Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias). Díaz-Beyá M, et al. Among authors: bargay j. Leukemia. 2014 Apr;28(4):804-12. doi: 10.1038/leu.2013.281. Epub 2013 Sep 27. Leukemia. 2014. PMID: 24072101
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J. Díaz-Beyá M, et al. Among authors: bargay j. Blood Cancer J. 2015 Oct 2;5(10):e352. doi: 10.1038/bcj.2015.76. Blood Cancer J. 2015. PMID: 26430723 Free PMC article.
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G; Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish Society of Hematology. Bernal T, et al. Among authors: bargay j. Leukemia. 2015 Sep;29(9):1875-81. doi: 10.1038/leu.2015.115. Epub 2015 May 6. Leukemia. 2015. PMID: 25943181 Free article.
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M, Malinverni R, Bargay J, Xicoy B, Marcé S, Garrido A, Tormo M, Arenillas L, Coll R, Borras J, Jiménez MJ, Hoyos M, Valcárcel D, Escoda L, Vall-Llovera F, Garcia A, Font LL, Rámila E, Buschbeck M, Zamora L; CETLAM group. Cabezón M, et al. Among authors: bargay j. Clin Epigenetics. 2021 Jan 14;13(1):9. doi: 10.1186/s13148-021-01002-y. Clin Epigenetics. 2021. PMID: 33446256 Free PMC article.
Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies.
Brunet S, Urbano-Ispizua A, Ojeda E, Ruiz D, Moraleda JM, Díaz MA, Caballero D, Bargay J, de la Rubia J, Solano C, Zuazu J, Diez JL, de la Serna J, Espigado I, Alegre A, Torres JP, Jurado M, Fernández M, Vivancos P, Carreras E, Hernández F, Maldonado J, Sierra J, Rozman C; Spanish Group of Allogenic-PBT, Spain. Brunet S, et al. Among authors: bargay j. Br J Haematol. 2001 Sep;114(3):544-50. doi: 10.1046/j.1365-2141.2001.03002.x. Br J Haematol. 2001. PMID: 11552978 Free article.
151 results